EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks

Sergii V Fedorchenko iD, Zhanna Klimenko, Tatiana Martynovich, Iryna Solianyk, Tatiana Suprunenko

Journal of Virology · 2025

DOI: 10.1128/jvi.01843-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Sergii V Fedorchenko und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease, Kyiv, Ukraine. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Antiviral Agents, Benzimidazoles, Quinoxalines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Volgograd State Medical University (VSMU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The outcomes of retreatment patients infected with hepatitis C virus genotype 3, cirrhosis, with velpatasvir may be affected by treatment failure with velpatasvir. The efficacy of SOF+GLE/PIB+RIB 16–24 weeks of treatment has been shown. The presence of NS5A resistance-associated substitution mutations, including Y93H, and the number and regimens of the past failed therapy do not influence the likelihood of achieving sustained virological response. When velpatasvir treatment fails, pibrentasvir should be used as the first choice for retreatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis C, ChronicAntiviral AgentsBenzimidazolesQuinoxalinesHepacivirusLiver CirrhosisHumansSofosbuvirPyrrolidinesSulfonamidesViral Nonstructural ProteinsRibavirinRetreatmentDrug Resistance, ViralMaleCarbamatesProlineTreatment FailureHeterocyclic Compounds, 4 or More RingsFemaleGenotypeDrug Therapy, CombinationMiddle AgedAminoisobutyric AcidsLactams, MacrocyclicSustained Virologic Response

Stichwörter der Autor:innen

antiviral agentshepatitis C virusmutationresistance

Substanzen

Antiviral AgentsSofosbuvirBenzimidazolesQuinoxalinesPyrrolidinesSulfonamidesViral Nonstructural ProteinsNS-5 protein, hepatitis C virusRibaviringlecaprevir and pibrentasvir

Autor:innen und Institutionen

  • Department of Viral Hepatitis and AIDS, The L.V. Gromashevskyi Institute of Epidemiology and Infectious Disease, Kyiv, Ukraine.

ORCID-Profile: Sergii V Fedorchenko

Förderung

  • Volgograd State Medical University (VSMU)

Zitieren

APA

Fedorchenko, S. V., Klimenko, Z., Martynovich, T., Solianyk, I., & Suprunenko, T. (2025). Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks. Journal of Virology. https://doi.org/10.1128/jvi.01843-24

Vancouver

Fedorchenko SV, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks. Journal of Virology. 2025. doi:10.1128/jvi.01843-24

BibTeX
@article{Fedorchenko2025,
  author = {Fedorchenko, Sergii V and Klimenko, Zhanna and Martynovich, Tatiana and Solianyk, Iryna and Suprunenko, Tatiana},
  title = {Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16–24 weeks},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01843-24}
}
Kostenlos starten →